Thanks to everyone who made this year’s Trans-Pacific Health Sciences Dialogue such a great success. We are grateful for the contributions of our attendees, speakers and sponsors that made this such a special event.
See you next year in Boston
Take a look at some photos from the 2014 Trans-Pacific Health Sciences Dialogue!
About the Conference
The Trans-Pacific Health Sciences Dialogue is a C-level meeting for biopharmaceutical industry executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America. This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.
Who Should Attend
The Trans-Pacific Health Sciences Dialogue is an invitation-only event for Asian and North American senior biopharmaceutical executives, KOLs and select professional industry advisors, service providers and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment. To request an invitation, please contact Lawrence Joseph.
Industry News from BioCentury
- CHMP recommends Newron's safinamide for PDEMA's CHMP recommended marketing authorization of safinamide from Newron Pharmaceuticals S.p.A. (SIX:NWRN) and partner Zambon Co. S.p.A. (Bresso, Italy) as add-on therapy to a stable dose of a dopamine agonist for patients with early PD, and as add-on therapy to levodopa alone or in combination with other treatments in patients with mid- to late-stage PD.
CHMP said the marketing authorization will include a pharmacovigilance plan.
Safinamide is an alpha-aminoamide derivative that acts as a reversible monoamine oxidase B (MAO-B) and dopamine reuptake inhibitor while reducing glutamatergic activity.
Newron submitted an NDA to FDA in June. Zambon has exclusive rights from Newron to develop and commercialize safinamide worldwide, excluding Asian territories where Meiji Seika Pharma Co. Ltd. (Tokyo, Japan) has rights.
Newron closed up CHF3.15 to CHF26.45 on Friday.
Industry News from PharmAsia
- PHARMAC Stressing Biosimilar Use For SavingsIn its annual review, the New Zealand pharmaceutical management agency PHARMAC says it has made substantial savings from switching to generics and is also now emphasizing the use of biosimilars.<img src="//feeds.feedburner.com/~r/_PharmAsiaNews/~4/05U-nY3IQ4Y" height="1" width="1" alt="" />
Upcoming Supporter Events
Life Science Future
October 13-14, 2014
Sheraton Downtown Hotel